No Data
No Data
Chison Medical Technologies' (SHSE:688358) Profits May Not Reveal Underlying Issues
Chison Medical Technologies Co., Ltd. (SHSE:688358) just released a solid earnings report, and the stock displayed some strength. Despite this, our analysis suggests that there are some factors weake
Chison Medical Technologies Co., Ltd. (SHSE:688358) Surges 15%; Private Companies Who Own 50% Shares Profited Along With Insiders
Key Insights Chison Medical Technologies' significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public The top 2 shareholders own 64%
Guoxin Securities released a research report on April 23 stating that it gave Xiangsheng Medical (688358.SH) a purchase rating. The main reasons for the rating include: 1) the 2023 performance grew rapidly, and the first quarter of 2024 was affected by th
Guoxin Securities released a research report on April 23 stating that it gave Xiangsheng Medical (688358.SH) a purchase rating. The main reasons for the rating include: 1) the 2023 performance grew rapidly, and the first quarter of 2024 was affected by the high base for the same period in 2023; 2) the cost ratio declined and the net interest rate increased; 3) the volume of portable devices driven overseas business growth; 4) the layout of cutting-edge artificial intelligence technology, and the product is in the clinical trial stage. (Mainichi Keizai Shimbun)
Xiangsheng Medical (688358): Net profit due to mother increased 38% in 2023, overseas business grew rapidly
Results grew rapidly in 2023, and the first quarter of 2024 was affected by the high base for the same period in 2023. In 2023, the company achieved revenue of 484 million yuan (+27.04%) and net profit of 146 million yuan to mother (+
Pharmaceutical and medical stocks fluctuated and rebounded | Tonghe Pharmaceutical and Wanfu Biotech rose more than 10%, while shares such as Yahuilong, Sannuo Biotech, Xiangsheng Healthcare, Betta Pharmaceuticals, Hanyu Pharmaceutical, and Eddy Pharmaceu
Pharmaceutical and medical stocks fluctuated and rebounded | Tonghe Pharmaceutical and Wanfu Biotech rose more than 10%, while shares such as Yahuilong, Sannuo Biotech, Xiangsheng Healthcare, Betta Pharmaceuticals, Hanyu Pharmaceutical, and Eddy Pharmaceuticals rose more than 5%.
Huafu Securities released a research report on April 21 stating that it gave Xiangsheng Medical (688358.SH) a purchase rating, with a target price of 43.01 yuan. The main reasons for the rating include: 1) the company released the 2023 annual report and t
Huafu Securities released a research report on April 21 stating that it gave Xiangsheng Medical (688358.SH) a purchase rating, with a target price of 43.01 yuan. The main reasons for the rating include: 1) the company released the 2023 annual report and the 2024 quarterly report; 2) the 2023 performance is in line with expectations, and the dividend ratio is impressive; 3) the overseas growth rate is excellent, the product structure continues to be optimized, and the continued high growth rate is expected; 4) As the research project continues, the introduction of new products will enable different clinical application scenarios. (Mainichi Keizai Shimbun)
No Data